Summary The patterns of early and late relapses (those occurring later than 3 years after diagnosis) in 432 patients achieving complete remission after treatment for stage I and 11 Hodgkin's disease at the Royal Marsden Hospital between 1964 and 1983 were studied to identify factors predicting for late relapse. The incidence of early relapse has fallen progressively in recent treatment eras as staging procedures and management have improved but in contrast there has been no decrease in the risk of late relapse. The incidence of late relapse was greater in patients treated with radiotherapy rather than combined modality therapy (P<0.05). However, patients who were clinically staged and treated with combined modality therapy retained as high a risk of relapse between 3 and 6 years as in years 2 and 3. The risk of late relapse was also greater in patients with stage II disease and in those without B symptoms at presentation. Patients falling into the higher risk categories for late relapse require continued close follow-up beyond 3 years to monitor for possible relapse.
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Early stage Hodgkin's disease has a good prognosis with modern management and prolonged survival is reported in about 80% of patients (Hoppe et al., 1982; Peckham et al., 1982; Tubiana et al., 1984) . A number of factors predicting for relapse and survival have been identified (Yarnold et al., 1982; Mill & Lee, 1982; Haybittle et al., 1985; , which has allowed selection of patients with poorrisk disease for treatment with combined modality therapy. Historically the majority of patients who relapsed did so within 3 years of their primary treatment (Herman et al., 1985) but the reduction in early relapses with the development of better staging and effective therapy has increased the proportion of patients at risk of late relapse.
We have undertaken a study of all adult patients with early stage Hodgkin's disease treated at the Royal Marsden Hospital between 1964 and 1983 to analyse the timing of relapse with changing management strategies and to identify factors predicting for late relapse which might determine the need for long-term follow-up. Table I .
Methods
Patients were treated with either radiotherapy alone or in combined modality treatment together with single agent or combination chemotherapy. Extended field irradiation was employed in the majority (96%) of patients to a dose of 40 Gy in 20 daily fractions, reduced to 35 Gy if prior chemotherapy had been given. If combined modality therapy was employed, six courses of MVPP or ChLVPP were given, followed after an interval of 6 weeks by radiotherapy. Sixteen patients were treated with combination chemotherapy alone.
Early relapse was defined .as relapse occurring within 3 years of the date of registration, with late relapses defined as those occurring beyond 3 years. All patients were followed for a minimum of 3 years so that all the early relapses were identified. Actuarial analyses of late relapses were calculated as the inverse of relapse-free survival for those patients remaining in remission at 3 years, to allow for the differences in length of follow-up which might influence the incidence of late relapse.
The risk of relapse was calculated for patients managed according to each of the following policies: either clinically or laparotomy-staged, and receiving either radiotherapy alone or combined modality therapy. For the purpose of these analyses the minority of patients receiving chemotherapy alone were included in the combined modality group, as patients who received a systemic treatment. The influence of known prognostic factors (age, stage, sex, syptoms and histological type) was evaluated using a log-rank analysis (Peto et al., 1977) , and their effect in determining either early or late relapse was examined using a x2 analysis. Those factors having independent prognostic significance for late relapse were identified using a stratified log-rank multivariate analysis. Figure 2 . The lower risk of late relapse in the combined modality group was due to the absence of late relapse in laparotomy-staged patients: the clinically staged combined modality patients had the Years after presentation (Haybittle et al., 1985) were examin their relevance to the timing of relapse. The factors is shown in Table II , which show relapse rate for each group at the end c between 3 and 12 years for those in remission effect of the prognostic factors on early rc previously reported examined further.
On univariate analysis presentation with 3) disease, age over 40 or without B predictive for late relapse in those patient remission at 3 years. Contrary to other (Herman et al., 1985) there was no significa relapses among patients with nodular scler the risk of late relapse increased marginally fi predominant to nodular sclerosing to mr histology (P=0.07). The only relapses ir lymphocyte-depleted histology occurred v whereas the balance between early and late differ significantly between the other histolo absence of B symptoms and the presence of than stage I disease retained their indepen significance for late relapse on multivariate Discussion The management of patients with Hodgki improved over the last two decades, due in 8/123 ments in radiotherapy, the introduction of combination chemotherapy and improved staging techniques, together with the identification of patients in whom the use of combined modality therapy may enhance the chances of 29/187 cure. The influence of these factors was seen as the falling risk of early and overall relapse rates over the two decades studied in this paper. In clinically staged, radiotherapytreated patients early relapse was common, reflecting the inadequacy of primary staging and treatment. The introduction of laparotomy staging reduced the risk of early relapse through the detection of many cases with occult infradiaphragmatic disease but the actuarial risk of late relapse in those remaining in remission at 3 years remained unchanged.
The use of combined modality therapy in conjunction with laparotomy staging in the majority of patients in the late 1970s reduced the risk of both early and late relapse.
Most recently, delineation of bad-risk prognostic factors The only reduction in the risk of late relapse with f stage II rather changing management policies was noted when combined dent prognostic modality therapy was used in conjunction with laparotomyanalysis.
staging, by which occult stage III cases would be excluded and all disease treated with both chemotherapy and irradiation. Justification of such aggressive approach to reduce late relapse rates might be difficult because of the added morbidity entailed. Careful follow-up of patients in the risk categories described above beyond the 3 years conventionally in's disease has accepted as cure continues to be required to detect late part to refinerelapse.
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